Pfizer (PFE)
(Delayed Data from NYSE)
$26.26 USD
+0.26 (1.00%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $26.25 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.26 USD
+0.26 (1.00%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $26.25 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Pfizer (PFE) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Why the Market Dipped But Pfizer (PFE) Gained Today
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
by Kinjel Shah
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
by Zacks Equity Research
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
by Zacks Equity Research
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International
by Zacks Equity Research
UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International are part of the Zacks top Analyst Blog.
Top Analyst Reports for UnitedHealth, Pfizer & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Incorporated (UNH), Pfizer Inc. (PFE) and BlackRock, Inc. (BLK).
Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal
by Zacks Equity Research
Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.
Pfizer (PFE) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $26.58, marking a -0.3% move from the previous day.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Pfizer (PFE) Stock Moves -0.11%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $27.72, marking a -0.11% move from the previous day.
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
by Zacks Equity Research
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $27.43, moving +0.26% from the previous trading session.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Pfizer (PFE) closed at $27.63 in the latest trading session, marking a -0.32% move from the prior day.
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
by Zacks Equity Research
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
The Zacks Analyst Blog Highlights Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer
by Zacks Equity Research
Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer are included in this Analyst Blog.